Clinical trials: Pancreatic Tumor
Pancreatic Cancer
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Pancreatic cancer (PC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. Progression after 1.
- Trial name
- INFLUENCE (NCT05116917)
- Testing
- Nivolumab, Ipilimumab, Influenza vaccine
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Herlev Hospital
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast…
- Conditions
- Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer
- Trial name
- NCT06384417
- Testing
- Hello for Cancer game, Table Topics game
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Milton S. Hershey Medical Center
Stage, Pancreatic Cancer, Neoplasm, Residual
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B…
- Conditions
- Stage, Pancreatic Cancer, Neoplasm, Residual, Pancreatic Neoplasm, Periampullary Cancer
- Trial name
- MPM (NCT02900950)
- Testing
- Multicolour inking specimens, Monocolour inking specimens
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Neuroendocrine Tumors, Parkinson Disease
- Trial name
- NCT03042416
- Testing
- 18F-DOPA
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of Alberta
Advanced Gastroenteropancreatic Neuroendocrine Tumor
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
- Trial name
- NCT05884255
- Testing
- Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide
- Where
- 2 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Adenocarcinoma
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA.
- Trial name
- NCT04902352
- Testing
- No Periadventitial dissection of the SMA, Periadventitial dissection of the SMA
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Pancreatic Cancer
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography…
- Trial name
- NCT00885248
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Asan Medical Center
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Pancreatic Cancer
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte ("Immuncell-LC") cell therapy in Gemcitabine refractory advanced pancreatic cancer
- Trial name
- NCT00965718
- Testing
- Activated T lymphocyte
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- GC Cell Corporation
Pancreatic Cancer
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer.
- Trial name
- NCT07114315
- Testing
- AK112, AK130
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
Pancreatic Cancer
A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
HRS-4642-103 is a single-center, single-arm, open-label, fixed-sequence study to investigate the effect of Itraconazole on the pharmacokinetics of HRS-4642 following intravenous infusion in healthy participants.
- Trial name
- NCT07906691
- Testing
- HRS4642, Itraconazole Capsules
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
This study is a single-arm phase I/II clinical study to evaluate the effectiveness of evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard…
- Trial name
- NCT06888648
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, mFOLFIRINOX Treatment Regimen, Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Pancreatic Cancer
Sequential Nutrition Intervention for Pancreatic Cancer Patients Undergoing CyberKnife Radiotherapy
This study aims to evaluate the clinical value of a structured nutritional support program for patients with pancreatic cancer undergoing CyberKnife radiotherapy.
- Trial name
- NCT07057843
- Testing
- Sequential Nutrition Intervention, Enteral Nutrition Emulsion, Routine Nutritional Intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Hospital of Hebei Medical University
Pancreatic Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00026403
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 26 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment
Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment
1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment…
- Trial name
- NCT06372886
- Testing
- portal/superior vein resection
- Volunteers
- 264 people
- Sponsor
- Seoul National University Hospital
Pancreas Cancer
Bethanechol Prior to Pancreatic Surgery
The primary objective of this study is to assess the impact of bethanechol therapy on tumor activity by looking at biomarkers of proliferation, inflammation, and stem cell markers in post-treatment specimens compared to…
- Trial name
- NCT03572283
- Testing
- Bethanechol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Columbia University
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Locally Advanced Pancreatic Adenocarcinoma
Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection
No comparative trial investigating the effect of preoperative chemotherapy for locally advanced pancreatic cancer on short-term postoperative outcome has been published so far.
- Trial name
- NCT01278368
- Testing
- Pancreatic resection after preoperative chemotherapy, Pancreatic resection
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Università Vita-Salute San Raffaele
Pancreatic Cancer, Periampullary Cancer
Prehabilitation in Pancreatic Surgery
In patients with pancreatic cancer, older age, multiple comorbidities, frailty, malnutrition and poor functional status are common, especially in individuals receiving neoadjuvant chemotherapy.
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Frailty Syndrome, Malnutrition
- Trial name
- PIPS (NCT06069297)
- Testing
- Multimodal Prehabilitation
- Where
- Italy
- Volunteers
- 238 people
- Sponsor
- IRCCS San Raffaele
Metastatic Pancreatic Cancer
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
- Trial name
- BrUOG-PA205 (NCT00439179)
- Testing
- cohort 1, cohort 2, cohort 3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Brown University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.